AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25376448 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg BIW for 12 weeks followed by 50 mg QW for 12 weeks
Number of subjects: 270
Study 25376448 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (ETN) 50 mg QW for 12 weeks followed by 50 mg QW for 12 weeks
Number of subjects: 270
Study 25376448 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg BIW/QW
Number of subjects: 270
Study 25376448 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (ETN) 50 mg QW/QW
Number of subjects: 270
Study 25376448 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe itching at baseline (score of 5)
Number of subjects: 270
Study 25376448 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patients with clinically meaningful pruritus improvement
Number of subjects: 270
Study 22743849 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency treatment (RFT) of the soft palate
Number of subjects: 32
Study 22743849 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiofrequency-assisted uvulopalatoplasty (RF-UPP)
Number of subjects: 32
Study 21211796 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical clowning after embryo transfer
Number of subjects: 0
Study 21211796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medical clowning)
Number of subjects: 0
Study 19061699 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial approach
Number of subjects: 3198
Study 19061699 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access
Number of subjects: 3198
Study 19061699 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 3198
Study 19061699 — intervention group
Group type: COMPARATOR
Intervention: Recent myocardial infarction
Number of subjects: 3198
Study 19061699 — intervention group
Group type: COMPARATOR
Intervention: Age (per 10 years increase)
Number of subjects: 3198
Study 19061699 — intervention group
Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 3198
Study 16873594 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face motivational interviewing plus telephone counseling and offering of medication
Number of subjects: 114
Study 16873594 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 114
Study 12635910 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype-consistent behavioral information
Number of subjects: 0
Study 12635910 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype-inconsistent behavioral information
Number of subjects: 0
Study 12635910 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype-neutral information
Number of subjects: 0
Study 11218882 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol used within 24 h after the onset (n = 46)
Number of subjects: 93
Study 11218882 — intervention group
Group type: COMPARATOR
Intervention: No mannitol used (n = 47)
Number of subjects: 93
Study 9338905 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN‐EPI
Number of subjects: 30
Study 9338905 — intervention group
Group type: COMPARATOR
Intervention: GEN
Number of subjects: 30
Study 8237823 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 8237823 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 8237823 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 0
Study 8237823 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 0
Study 3847416 — intervention group
Group type: EXPERIMENTAL
Intervention: Method A
Number of subjects: 50
Study 3847416 — intervention group
Group type: EXPERIMENTAL
Intervention: Method B
Number of subjects: 50
Study 31344434 — intervention group
Group type: COMPARATOR
Intervention: Single fraction palliative radiation therapy (8 Gy)
Number of subjects: 0
Study 31344434 — intervention group
Group type: COMPARATOR
Intervention: Fractionated palliative radiation therapy (24 Gy in 6 fractions)
Number of subjects: 0
Study 31344434 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients whose pain improved after palliative radiation therapy
Number of subjects: 0
Study 31344434 — intervention group
Group type: COMPARATOR
Intervention: Single fraction palliative radiation therapy (8 Gy) including reirradiation
Number of subjects: 0
Study 31344434 — intervention group
Group type: COMPARATOR
Intervention: Fractionated palliative radiation therapy (24 Gy in 6 fractions) including reirradiation
Number of subjects: 0
Study 30104895 — intervention group
Group type: COMPARATOR
Intervention: Laser Disc Decompression Group (LDG) - 1500 J of laser irradiation into the disc center
Number of subjects: 40
Study 30104895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone Injection Group (OZG) - 6 mL of ozone 30 µg/mL injected into the center of the disc
Number of subjects: 40
Study 27434505 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine buccal film (BBUP)
Number of subjects: 511
Study 27434505 — intervention group
Group type: COMPARATOR
Intervention: Placebo buccal film
Number of subjects: 511
Study 25420433 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstracts with a limitations section
Number of subjects: 300
Study 25420433 — intervention group
Group type: COMPARATOR
Intervention: Abstracts without a limitations section
Number of subjects: 300
Study 19793332 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinylsiloxanether (ID)
Number of subjects: 10
Study 19793332 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinylsiloxanether with additional splinting (IDF)
Number of subjects: 10
Study 19793332 — intervention group
Group type: COMPARATOR
Intervention: Polyether (IM)
Number of subjects: 10
Study 21034888 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide-based formula with 3.5 g fructo-oligosaccharides and 3.8 g insoluble fiber/L
Number of subjects: 14
Study 21034888 — intervention group
Group type: COMPARATOR
Intervention: Control formula (fiber-free)
Number of subjects: 14
Study 18579709 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive workshops on chlamydia
Number of subjects: 82
Study 18579709 — intervention group
Group type: COMPARATOR
Intervention: Control workshops on management of urinary symptoms
Number of subjects: 82
Study 18579709 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified laboratory request forms
Number of subjects: 82
Study 16045137 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2%
Number of subjects: 91
Study 16045137 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine 0.75%
Number of subjects: 91
Study 14508939 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective bandage
Number of subjects: 130
Study 14508939 — intervention group
Group type: COMPARATOR
Intervention: Allevyn Heel hydrocellular dressing
Number of subjects: 130
Study 10367542 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharose (10% solution, 100 ml)
Number of subjects: 22
Study 10367542 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (10% solution, 100 ml)
Number of subjects: 22
Study 10367542 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (10% solution, 100 ml)
Number of subjects: 22
Study 10367542 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomalt (10% solution, 100 ml)
Number of subjects: 22
Study 7669959 — intervention group
Group type: EXPERIMENTAL
Intervention: R 80122 (n = 6)
Number of subjects: 12
Study 7669959 — intervention group
Group type: COMPARATOR
Intervention: Solvent (n = 6)
Number of subjects: 12
Study 2343719 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation by experienced senior anaesthetist
Number of subjects: 198
Study 2343719 — intervention group
Group type: COMPARATOR
Intervention: Ventilation by inexperienced junior anaesthetist
Number of subjects: 198
Study 7039645 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia plus extradural analgesia (T8‐S5)
Number of subjects: 13
Study 7039645 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (halothane and nitrous oxide)
Number of subjects: 13
Study 31909887 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg/day isoniazid (INH)
Number of subjects: 24
Study 31909887 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg/day isoniazid (INH)
Number of subjects: 24
Study 30900406 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid meal condition
Number of subjects: 42
Study 30900406 — intervention group
Group type: COMPARATOR
Intervention: Water condition
Number of subjects: 42
Study 28461159 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (200,000 IU initial dose followed by 100,000 IU monthly)
Number of subjects: 5110
Study 28461159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5110
Study 26823746 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume of 7 ml/kg IBW with 8 cm H2O PEEP and recruitment
Number of subjects: 63
Study 26823746 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume of 7 ml/kg IBW with 8 cm H2O PEEP
Number of subjects: 63
Study 26823746 — intervention group
Group type: COMPARATOR
Intervention: High volume of 9 ml/kg IBW with ZEEP
Number of subjects: 63
Study 24816611 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching intervention (11 sessions over 6 months)
Number of subjects: 410
Study 24816611 — intervention group
Group type: COMPARATOR
Intervention: Usual-care (control) group
Number of subjects: 410
Study 24816611 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching intervention (in survivors aged > 60 years)
Number of subjects: 410
Study 24816611 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching intervention (in male survivors)
Number of subjects: 410
Study 24816611 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching intervention (in nonobese survivors)
Number of subjects: 410
Study 23017825 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory
Number of subjects: 117
Study 23017825 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative symptoms
Number of subjects: 117
Study 23017825 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognition
Number of subjects: 117
Study 23017825 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal learning
Number of subjects: 117
Study 23017825 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual learning
Number of subjects: 117
Study 23017825 — intervention group
Group type: EXPERIMENTAL
Intervention: General symptoms
Number of subjects: 117
Study 19338691 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up intervention
Number of subjects: 731
Study 17295604 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 42
Study 17295604 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg/d)
Number of subjects: 42
Study 17295604 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg/twice weekly)
Number of subjects: 42
Study 15114301 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (Certoparin 3000 IU subcutaneously)
Number of subjects: 448
Study 15114301 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution 0.3 mL subcutaneously)
Number of subjects: 448
Study 15114301 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 448
Study 15114301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study 11504286 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium insufflation
Number of subjects: 18
Study 11504286 — intervention group
Group type: COMPARATOR
Intervention: CO2 insufflation
Number of subjects: 18
Study 9467533 — intervention group
Group type: COMPARATOR
Intervention: TRH
Number of subjects: 20
Study 9467533 — intervention group
Group type: COMPARATOR
Intervention: TRH + GHRP-2
Number of subjects: 20
Study 9467533 — intervention group
Group type: COMPARATOR
Intervention: TRH + GHRH + GHRP-2
Number of subjects: 20
Study 9467533 — intervention group
Group type: COMPARATOR
Intervention: GHRP-2
Number of subjects: 20
Study 9467533 — intervention group
Group type: COMPARATOR
Intervention: GHRH + GHRP-2
Number of subjects: 20
Study 9467533 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH + GH secretagogues
Number of subjects: 20
Study 9467533 — intervention group
Group type: COMPARATOR
Intervention: TRH alone
Number of subjects: 20
Study 7841946 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage at -80 degrees C
Number of subjects: 0
Study 7841946 — intervention group
Group type: COMPARATOR
Intervention: Storage at -20 degrees C
Number of subjects: 0
Study 7841946 — intervention group
Group type: COMPARATOR
Intervention: Storage at room temperature for 2 weeks
Number of subjects: 0
Study 7841946 — intervention group
Group type: COMPARATOR
Intervention: Storage at 4 degrees C for 5 weeks
Number of subjects: 0
Study 7841946 — intervention group
Group type: COMPARATOR
Intervention: Storage at -40 degrees C
Number of subjects: 0
Study 3045278 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnoy's fixation
Number of subjects: 0
Study 3045278 — intervention group
Group type: COMPARATOR
Intervention: Formalin fixation
Number of subjects: 0
Study 31751163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg plus carboplatin plus paclitaxel or nab-paclitaxel
Number of subjects: 1107
Study 31751163 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carboplatin plus paclitaxel or nab-paclitaxel
Number of subjects: 1107
Study 31751163 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (pembrolizumab and placebo)
Number of subjects: 1107
Study 29506561 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo adherence (at least 80%)
Number of subjects: 0
Study 29506561 — intervention group
Group type: COMPARATOR
Intervention: Placebo non-adherence (never adhered)
Number of subjects: 0
Study 27316483 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 5 mg twice daily for 6 weeks
Number of subjects: 82
Study 27316483 — intervention group
Group type: COMPARATOR
Intervention: atenolol 50 mg daily for 6 weeks
Number of subjects: 82
Study 27316483 — intervention group
Group type: COMPARATOR
Intervention: ivabradine vs atenolol
Number of subjects: 82
Study 27316483 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 82
Study 27316483 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 82
Study 25795621 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (oscillating square wave tDCS)
Number of subjects: 12
Study 25795621 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study 23106175 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group intervention (residential for one week, followed by four days of follow-up two months later)
Number of subjects: 382
Study 23106175 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group intervention
Number of subjects: 382
Study 23106175 — intervention group
Group type: COMPARATOR
Intervention: Routine control group
Number of subjects: 382
Study 20646562 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) without low molecular heparin (LMWH)
Number of subjects: 0
Study 20646562 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) combined with low molecular heparin (LMWH)
Number of subjects: 0
Study 20646562 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled intravenous analgesia (PCIA) without low molecular heparin (LMWH)
Number of subjects: 0
Study 20646562 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled intravenous analgesia (PCIA) combined with low molecular heparin (LMWH)
Number of subjects: 0
Study 18653492 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (2.0 mg kg(‐1)) administered at reappearance of the second twitch of the TOF.
Number of subjects: 30
Study 16580371 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH)
Number of subjects: 172
Study 16580371 — intervention group
Group type: COMPARATOR
Intervention: Control group (no assisted hatching)
Number of subjects: 172
Study 12770960 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 84
Study 12770960 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 84
Study 12770960 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study 10997756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular resynchronization therapy alone
Number of subjects: 0
Study 10997756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular resynchronization therapy combined with cardioverter-defibrillator capability
Number of subjects: 0
Study 10997756 — intervention group
Group type: COMPARATOR
Intervention: Optimal pharmacological therapy alone
Number of subjects: 0
Study 9057141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing with reaming
Number of subjects: 81
Study 9057141 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary nailing without reaming
Number of subjects: 81
Study 8116822 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-Step Facilitation
Number of subjects: 0
Study 8116822 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Coping Skills
Number of subjects: 0
Study 8116822 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Number of subjects: 0
Study 3734141 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 24
Study 3734141 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 20 mg
Number of subjects: 24
Study 3734141 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 24
Study 3734141 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol 0.8 g/kg
Number of subjects: 24
Study 3734141 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 24
Study 3734141 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 24
Study 3734141 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam and Alcohol interaction
Number of subjects: 24
Study 3734141 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone and Alcohol interaction
Number of subjects: 24
Study 3734141 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone and Diazepam pharmacokinetics
Number of subjects: 24
Study 3734141 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of buspirone
Number of subjects: 24
Study 29473354 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Dachangshu (BL 25) and Shangjuxu (ST 37) combined with ulinastatin, treatment duration: 2 weeks, frequency: once daily for 20 minutes.
Number of subjects: 120
Study 29473354 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine with intravenous drip of ulinastatin (Control group).
Number of subjects: 120
Study 29473354 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Dachangshu (BL 25) and Shangjuxu (ST 37) combined with ulinastatin.
Number of subjects: 120
Study 26816234 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day of Physta® standardized root water extract of Eurycoma longifolia (Tongkat Ali) for 4 weeks
Number of subjects: 84
Study 26816234 — intervention group
Group type: COMPARATOR
Intervention: Rice powder as placebo for 4 weeks
Number of subjects: 84
Study 24751172 — intervention group
Group type: COMPARATOR
Intervention: CMX-2043
Number of subjects: 0
Study 23605952 — intervention group
Group type: EXPERIMENTAL
Intervention: Barasertib 1200 mg (7-day intravenous infusion)
Number of subjects: 74
Study 23605952 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cytosine arabinoside (LDAC) 20 mg (subcutaneously twice daily for 10 days)
Number of subjects: 74
Study 23605952 — intervention group
Group type: EXPERIMENTAL
Intervention: Barasertib
Number of subjects: 74
Study 23605952 — intervention group
Group type: COMPARATOR
Intervention: LDAC
Number of subjects: 74
Study 19952712 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 50
Study 19952712 — intervention group
Group type: COMPARATOR
Intervention: Continued protease inhibitor regimen
Number of subjects: 50
Study 18720881 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine and normal sodium spray
Number of subjects: 50
Study 18720881 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine and Nasonex spray
Number of subjects: 50
Study 18720881 — intervention group
Group type: COMPARATOR
Intervention: Placebo and normal sodium spray
Number of subjects: 50
Study 15820828 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal bromocriptine suppositories with Pluronic F127
Number of subjects: 0
Study 15820828 — intervention group
Group type: COMPARATOR
Intervention: Vaginal application of bromocriptine tablets
Number of subjects: 0
Study 12680813 — intervention group
Group type: EXPERIMENTAL
Intervention: Information plus role-play experience
Number of subjects: 0
Study 12680813 — intervention group
Group type: COMPARATOR
Intervention: Information alone
Number of subjects: 0
Study 10230004 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization with plaster cast
Number of subjects: 33
Study 10230004 — intervention group
Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 33
Study 10230004 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (dominant and non-dominant injured side)
Number of subjects: 33
Study 10230004 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dominant injured side
Number of subjects: 33
Study 10230004 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain during measurements
Number of subjects: 33
Study 8917026 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ranitidine at 6.25 mg/hr (n = 9)
Number of subjects: 20
Study 8917026 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 20
Study 1679446 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% isopropanol (IPA) applied for 2 min
Number of subjects: 0
Study 1679446 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% isopropanol (IPA) applied for 30 s
Number of subjects: 0
Study 1679446 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiscrub (chlorhexidine scrub)
Number of subjects: 0
Study 1679446 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine scrubs (four types)
Number of subjects: 0
Study 1679446 — intervention group
Group type: COMPARATOR
Intervention: 7.5% povidone-iodine scrub
Number of subjects: 0
Study 1679446 — intervention group
Group type: COMPARATOR
Intervention: 2% triclosan cleanser
Number of subjects: 0